Following Fresenius

Keyword Search

EuroWeek.com Home

EuroWeek.com Daily

Asia Bank Finance Corporate Financing Equity Emerging Markets Loans

League Tables

Email Article

COMMENT ON THIS ARTICLE

All comments are subject to editorial review.
All fields are compulsory

Your name:
Please enter your name
Your email: (will not appear)
Please enter your email Please enter a valid email
Comments:
Please enter a comment
Publish your name?
Receive notifications?
Email yourself a copy?
You may email your comment to a friend To include more than one recipient, please separate each email address with a semi-colon ';'
Recipient email(s):
Please enter valid email addresses
Enter the code:	Please enter the correct code below

EMAIL A FRIEND

All comments are subject to editorial review.
All fields are compulsory

Your name:
Please enter your name
Your email:
Please enter your email address Please enter a valid email
To include more than one recipient, please seperate each email address with a semi-colon ';'
Recipient email(s):
Please enter valid email addresses with no spaces
Email yourself a copy?
Comments:
Enter the code:	Please enter the correct code below

LEVERAGED FINANCE

Issue: 1146 - 16 March 2010

German healthcare group Fresenius showed its might last week when it amended a $1.2bn syndicated loan, as a result cutting its interest payments substantially. It’s not just good news for the company: if history is a guide, then where Fresenius goes, others soon follow. ..

The rest of this article is available to subscribers and active trials only.

Please contact Jeremy Masters to start your access: jmasters@euroweek.com or click here to start a free trial.

New to EuroWeek?

Register for your free trial now. It’s a quick process that gives you the same access as subscribers to the EuroWeek site for a trial period. Get all of the latest news, comment and analysis on the capital markets.

Subscribe today to start your full access to EuroWeek. Receive all the news straight to your inbox, sector-specific special reports and EuroWeek’s comprehensive news and coverage of the industry.

Already Registered?

Please enter your email address and password below to log in and read the rest of this article.
If you are experiencing any difficulty, please call +44(0)20 7779 8036 or email jmasters@euroweek.com.

Welcome, guest Login

Corporate Subscriptions

Your department or entire company can receive the latest EuroWeek news online. Please call us on +44 (0)20 7779 8036 to discuss your exact requirements and we will tailor your subscription rate accordingly.